Research programme: neurodegenerative disease therapeutics - Neuronascent

Drug Profile

Research programme: neurodegenerative disease therapeutics - Neuronascent

Alternative Names: NNI-362; NNI-370

Latest Information Update: 09 Feb 2015

Price : $50

At a glance

  • Originator Neuronascent
  • Class Small molecules
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease
  • Research Parkinson's disease

Most Recent Events

  • 05 Feb 2015 Neuronascent receives patent allowance for NNI 362 in USA
  • 21 Nov 2013 Clinical candidates are available for licensing as of 19 Nov 2013. https://www.neuronascent.com
  • 06 May 2012 Preclinical development is ongoing in Alzheimer's disease and early research is ongoing in Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top